News | May 11, 2021
Vivimed Labs to manufacture, market Favipiravir tablets
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
Baricitinib is used in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
The facility is expected to be completed in 2024
Dorzolamide Hydrochloride and Timolol Maleate Ophthalmic Solution USP, 2% and 0.5% has an estimated market size of US $80 million for twelve months ending December 2020 according to IQVIA
Seven manufacturers of Remdesivir have increased production capacity to 1.03 crore vials per month up from 38 lakh vials per month a month ago
The company will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic
As of 2nd May 2021, the Government has provided more 16.54 crore COVID-19 vaccine doses to States/UTs free of cost
Subscribe To Our Newsletter & Stay Updated
